Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Trastuzumab treatment in patients with breast cancer and metastatic CNS disease.

Pieńkowski T, Zielinski CC.

Ann Oncol. 2010 May;21(5):917-24. doi: 10.1093/annonc/mdp353. Epub 2009 Aug 28. Review.

PMID:
19717536
2.

Defining prognosis for women with breast cancer and CNS metastases by HER2 status.

Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, Aldape KD, Yu TK, Hortobagyi GN, Gonzalez-Angulo AM.

Ann Oncol. 2008 Jul;19(7):1242-8. doi: 10.1093/annonc/mdn036. Epub 2008 Mar 11.

PMID:
18334512
3.

Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.

Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P.

Ann Oncol. 2005 Nov;16(11):1772-7. Epub 2005 Sep 8.

PMID:
16150805
4.

Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases.

Leyland-Jones B.

J Clin Oncol. 2009 Nov 1;27(31):5278-86. doi: 10.1200/JCO.2008.19.8481. Epub 2009 Sep 21. Review.

PMID:
19770385
5.

Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab.

Montagna E, Cancello G, D'Agostino D, Lauria R, Forestieri V, Esposito A, Silvestro L, Accurso A, De Placido S, De Laurentiis M.

Cancer Chemother Pharmacol. 2009 Jan;63(2):275-80. doi: 10.1007/s00280-008-0737-3. Epub 2008 Apr 1.

PMID:
18379783
6.
7.

Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.

Musolino A, Ciccolallo L, Panebianco M, Fontana E, Zanoni D, Bozzetti C, Michiara M, Silini EM, Ardizzoni A.

Cancer. 2011 May 1;117(9):1837-46. doi: 10.1002/cncr.25771. Epub 2010 Nov 10.

8.
9.

Central nervous system metastases in breast cancer patients administered trastuzumab.

Duchnowska R, Szczylik C.

Cancer Treat Rev. 2005 Jun;31(4):312-8. Review.

PMID:
15979804
10.

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.

Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E.

Cancer. 2003 Jun 15;97(12):2972-7.

11.

Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab.

Olson EM, Abdel-Rasoul M, Maly J, Wu CS, Lin NU, Shapiro CL.

Ann Oncol. 2013 Jun;24(6):1526-33. doi: 10.1093/annonc/mdt036. Epub 2013 Mar 4.

12.

Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer.

Park IH, Ro J, Lee KS, Nam BH, Kwon Y, Shin KH.

Ann Oncol. 2009 Jan;20(1):56-62. doi: 10.1093/annonc/mdn539. Epub 2008 Jul 29.

PMID:
18664558
13.

The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.

Tokuda Y, Suzuki Y, Saito Y, Umemura S.

Breast Cancer. 2009;16(4):295-300. doi: 10.1007/s12282-009-0142-8. Epub 2009 Jul 17. Review.

PMID:
19609647
14.

A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.

Larsen PB, Kümler I, Nielsen DL.

Cancer Treat Rev. 2013 Nov;39(7):720-7. doi: 10.1016/j.ctrv.2013.01.006. Epub 2013 Mar 5. Review.

PMID:
23481218
15.

Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier.

Mehta AI, Brufsky AM, Sampson JH.

Cancer Treat Rev. 2013 May;39(3):261-9. doi: 10.1016/j.ctrv.2012.05.006. Epub 2012 Jun 22. Review.

16.

Treatment of brain metastases in patients with HER2+ breast cancer.

Bravo Marques JM.

Adv Ther. 2009 Jul;26 Suppl 1:S18-26. doi: 10.1007/s12325-009-0047-0. Epub 2009 Jul 24. Review.

PMID:
19669638
17.

Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy.

Montemurro F, Donadio M, Clavarezza M, Redana S, Jacomuzzi ME, Valabrega G, Danese S, Vietti-Ramus G, Durando A, Venturini M, Aglietta M.

Oncologist. 2006 Apr;11(4):318-24.

18.

Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors.

Gori S, Rimondini S, De Angelis V, Colozza M, Bisagni G, Moretti G, Sidoni A, Basurto C, Aristei C, Anastasi P, Crinò L.

Oncologist. 2007 Jul;12(7):766-73.

19.

Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment.

Xiao C, Gong Y, Han EY, Gonzalez-Angulo AM, Sneige N.

Ann Oncol. 2011 Jul;22(7):1547-53. doi: 10.1093/annonc/mdq623. Epub 2011 Jan 14.

PMID:
21239403
20.

Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.

Morris SR, Carey LA.

Oncology (Williston Park). 2006 Dec;20(14):1763-71; discussion 1771-2, 1774-6. Review.

Supplemental Content

Support Center